Cenvacibart
Monoclonal antibody
Also known as REGN7508
Evidence outlook · registrational
Venous Thromboembolism: registrational readout pending
Its supporting mid-stage studies have completed. Registrational readout expected around 2027-02-20.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Factor XI drugs
SHR-2004, Gruticibart, SRSD107, Amrecibart. Compare all 5 Factor XI drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Venous Thromboembolism: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cenvacibart: this drug | Phase 3 | Monoclonal antibody | Factor XI | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-2004 | Phase 3 | Undisclosed | Factor XI | not yet graded | No reviewed efficacy summary in this indication | |
| Gruticibart | Phase 2(overall) | Monoclonal antibody | Factor XI | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| SRSD107 | Phase 2 | RNA / oligonucleotide | Factor XI | not yet graded | No reviewed efficacy summary in this indication | |
| Amrecibart | Phase 1(overall) | Monoclonal antibody | Factor XI | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(12 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Cenvacibart to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.